Genes Associated with Age-Related Hearing Loss Visualized in New Study
UPPSALA, SWEDEN — Researchers from Uppsala University have been able to document and visualize hearing loss-associated genes in the human inner ear, in a unique collaboration study between otosurgeons and geneticists. The findings illustrate that discrete subcellular structures in the human organ of hearing, the cochlea, are involved in the variation of risk of age-related…
Read More
Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as…
Read More
New Stem Cell Technique May Help Treat Common Hereditary Deafness, Say Researchers
TOKYO, JAPAN — Researchers at Juntendo University report in the journal Human Molecular Genetics that a stem-cell technique may be used to develop a treatment of a common mutation-related type of deafness. The method involves reproducing cells occurring in the human inner ear where the researchers emphasize that ‘the pathological condition could be reproduced with…
Read More
Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss
BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for AK-OTOF, a gene therapy intended…
Read More
Researchers Develop Genetic Patch to Prevent Hereditary Deafness
NIJMEGEN, NETHERLANDS — They can hear well up to about forty years old, but then suddenly deafness strikes people with DFNA9. The cells of the inner ear can no longer reverse the damage caused by a genetic defect in their DNA. Researchers at Radboud university medical center have now developed a “genetic patch” for this…
Read More
Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing treatments to restore and improve hearing and balance, has announced a partnership with Invitae, a leading medical genetics company, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy.…
Read More
Akouos and Blueprint Genetics Announce Resonate Program to Improve Access to Genetic Testing for Auditory Neuropathy
BOSTON, MASSACHUSSETTS – Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, and Blueprint Genetics, a Quest Diagnostics company, today announced the Resonate program. The program offers genetic testing to eligible individuals with auditory neuropathy at no cost to participants, their…
Read More
Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, has announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with…
Read MoreAkouos Announces Key Leadership Appointments
BOSTON, MASSACHUSSETTS — Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer, effective today. In addition, the company announced that Jennifer Wellman has been promoted to chief operating officer, from her prior…
Read More
Akouos Announces Expansion of Executive Team and Board of Directors
BOSTON, MASSACHUSSETTS — Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Alan Smith, Ph.D., as chief technology officer. In addition, the company announced that Saira Ramasastry has been appointed to its board of directors as…
Read More